Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
the SafeHer Study Group
نتاج البحث: المساهمة في مجلة › Article › مراجعة النظراء
41
اقتباسات
(Scopus)